Amyloid Study Pinpoints Protein Culprits
News Nov 02, 2016
Researchers from The University of Queensland and the Princess Alexandra Hospital Amyloidosis Centre used a new test to identify the specific protein that caused the damage in each patient.
Associate Professor Michelle Hill from the UQ Diamantina Institute said different amyloid conditions had different protein culprits, and required different treatments.
“For instance, in one type of amyloidosis known as AL, chemotherapy is required, but chemo is inappropriate and potentially harmful to patients with other amyloid conditions,” Dr Hill said.
“In the trial we used cutting-edge techniques including laser-capture microdissection and tandem mass spectrometry to identify proteins in the amyloid deposits.
“This technique was recently reported by the Mayo Clinic in the United States as a new diagnostic tool for amyloidosis, but it has not yet been evaluated in other centres.
“It is a challenging technique because of the small size of the protein deposits and the technical skills required for the multiple steps of the method.
“We were pleased to be able to identify amyloid proteins in 121 out of 131 attempted cases in this study, a success rate of 92 per cent.”
The PAH Amyloidosis Centre is the only centre in Australia to provide mass spectrometry analysis for amyloidosis patients.
Centre Director Dr Peter Mollee said the assay’s accuracy was a significant improvement on traditional laboratory tests.
“We tested previous methods on a subset of the samples from this study and the success rate was only 45 per cent,” Dr Mollee said.
“Strikingly, during the course of the five-year trial, the mass spectrometry assay results altered the diagnosis in almost a quarter of all cases.
“This is a big step forward for amyloid patients because identifying the culprit protein is so important to delivering the right treatment.”
The centre now receives referrals from across Australasia for the mass spectrometry test, which is performed at the Translational Research Institute Proteomics and Mass Spectrometry Core Facility.
The research, published in Clinical Proteomics, was a collaboration between clinicians and UQ scientists based at the Princess Alexandra Hospital campus.
The study was funded by the PA Research Foundation, Pathology Queensland, the Australian Cancer Research Foundation and the National Health and Medical Research Council (NHMRC).
Story from University of Queensland. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Mollee, P., Boros, S., Loo, D., Ruelcke, J. E., Lakis, V. A., Cao, K. L., Renaut, P., Hill, M. M. (2016). Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry. Clinical Proteomics, 13(1). doi:10.1186/s12014-016-9133-x
New Microfluidic Chip Boosts the Sensitivity of Immunoassays by >1000xNews
The chip works well even when protein biomarkers are present in extremely small numbers, as is the situation during the early stages of a disease.READ MORE
UVA Health Enlists Robotic Help to Enhance Blood TestingNews
The system has revolutionized how it tests patient blood samples, automating its primary testing facility with high-tech robots that are getting doctors the results they need quickly and efficiently – and allowing UVA to offer a wider range of blood tests, to boot.